{"slug":"pancragen","seoKey":"pancragen","displayName":"Pancragen","codes":["KEDW","KEDW-NH2","АКС-П"],"synonyms":["Lys-Glu-Asp-Trp","Lys-Glu-Asp-Trp-NH2","KEDW","lysyl-glutamyl-aspartyl-tryptophanamide (the NLM MeSH supplementary concept heading, UID 67531938)","Pankragen / Панкраген (Russian trade name)","Pancragene (spelling used in PMID 18225766)","Pankragen forte (the 500 µg form used in PMID 28976155)","H-Lys-Glu-Asp-Trp-OH (the free acid declared by Western sellers, not the form of the published work)"],"legalClass":"research_chemical","identifiers":{"formula":"C26H37N7O8","molecularWeight":575.62,"sequence":"Lys-Glu-Asp-Trp-NH2"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not registered as a substance. Four federal queries returned no match on 2026-09-20: no drug label in the openFDA labelling data, where a control query for an approved medicine returned eighteen labels; no entry in the labelling database searched by drug name; no record in the substance registration system, which is why there is no unique ingredient identifier; and no adverse event report. The substance also appears in none of the three categories of the list of bulk substances nominated for pharmacy compounding, whose full text was downloaded and searched for the trade name, the sequence and the abbreviation, while a control term in the same document was found, so it was never even nominated for review. Distribution runs through the research-chemical channel with a research-use-only label, and no marketing as a dietary supplement was found.","source":"https://api.fda.gov/drug/label.json?search=%22pancragen%22"},{"market":"EU","status":"not_approved","note":"No centralised marketing authorisation, no assessment report and no withdrawal document. The register itself could not be queried on 2026-09-20, the site refusing the request with HTTP 403 directly and HTTP 401 through a fetching service. The negative finding therefore rests on the complete absence of the substance from every other authority database that could be checked, on the absence of any assigned classification code and on the absence of any registered clinical trial, not on a primary regulator document. Separately from medicines law, no food status follows either: a synthetic tetrapeptide without documented consumption in the Union before 15 May 1997 falls under the novel food rules, whatever its status in Russia.","source":"https://www.ema.europa.eu/en/medicines"},{"market":"DE","status":"not_approved","note":"Neither a national nor a European marketing authorisation exists, so the injected preparation is not a marketable medicinal product and may not be imported or dispensed. It is not a narcotic either, and it is not named in the schedule to the anti-doping act: that schedule's full text was searched on 2026-09-20 for the trade name, the sequence and the abbreviation without a hit, while a listed substance in the same text was found as a control. The schedule lists what it covers by name, from erythropoiesis-stimulating substances through growth hormone fragments to releasing hormones, and there is no catch-all position for peptides. Sporting rules are unaffected by that. The Russian capsule is a food supplement there; importing it as a food would have to clear the novel food rules separately.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"No marketing authorisation known. The product register could not be evaluated on 2026-09-20: the search returned only the JavaScript shell of the search page, some 122,000 bytes without any server-rendered result, and the control search behaved the same way. This is recorded as an unverified gap rather than as a confirmed negative finding, and the assessment rests on the absence of any entry in every other register that could be queried and on the absence of any clinical development.","source":"https://products.mhra.gov.uk/search/?search=pancragen"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard; the full text of the June 2026 instrument was searched on 2026-09-20 for the trade name, the transliteration, the sequence and the abbreviation without a hit, while a control term in the same document was found, so this is a real absence rather than a failed query. Absence of a listing is not a clearance: an unlisted substance with a therapeutic purpose falls under the rules for unregistered therapeutic goods, and unapproved research peptides are treated in practice much like prescription-only substances. The register of therapeutic goods itself could not be queried, its interface returning HTTP 500 on that date.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no entry in the drug product database; the query for the trade name returned an empty result on 2026-09-20, while a control query for an authorised medicine returned records with its identification number, so the interface was working and the negative finding is verified.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&brandname=pancragen"},{"market":"CH","status":"not_approved","note":"No marketing authorisation known. No direct register query was possible on 2026-09-20, the page called returning HTTP 404. Since the substance is held as a medicine in none of the registers checked worldwide, has no registered clinical trial anywhere and is sold in its country of origin as a food supplement rather than a medicine, a Swiss-only authorisation would be extraordinarily unlikely, but it is not positively ruled out.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":[],"lastVerified":"2026-09-20","version":"1.0","published":true,"locale":"en","title":"Pancragen: what the studies show, status and safety","summary":"Pancragen is a synthetic chain of four amino acids from a St Petersburg institute, assigned to the pancreas and sold for blood sugar. No trial of it has ever been registered anywhere. People received it on three recorded occasions, none registered, none blinded and none independently reviewed, and on the best documented of them only half of twelve participants showed the reported change. It is approved as a medicine nowhere and banned in sport at all times.","updated":"2026-09-20","url":"https://mypep.app/peptides/pancragen"}